Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease
← catalyst calendarNCT07271186 · readout in 401 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
270estimated
Sites
58
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-09 | actual | When the study began enrolling |
| Primary completion | 2027-09-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-07 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetic Kidney Disease (DKD)
Interventions
- Drug: ALN-ANG3
- Drug: Evinacumab — also filed as Evkeeza®, R1500
- Drug: ALN-ANG3 placebo
- Drug: Evinacumab placebo
Primary outcome
what the primary-completion date above is the date OFPercent change in Urine Albumin to Creatinine Ratio (UACR)
measured Baseline to Week 24
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed